iRhythm completes $237.5 M acquisition of VitalConnect, adding multi‑vitals monitoring
iRhythm Holdings announced that it has closed its purchase of VitalConnect, a wearable biosensor firm. The transaction consists of $237.5 million in cash, up to 423,334 iRhythm shares and a $10.0 million working‑capital contribution. The combined company expects the deal to accelerate revenue growth beginning in 2027 while keeping an adjusted EBITDA margin of 15% for that year.
Why it matters
The company says the acquisition will broaden its cardiac monitoring portfolio and expand its addressable market across inpatient, remote and hospital‑to‑home settings, which should lift revenue growth from 2027 onward. Maintaining the 15% adjusted EBITDA margin target signals that profitability expectations remain unchanged despite the added scale.
Key facts
- 1The purchase price includes $237.5 million in cash. globenewswire.com
- 2Up to 423,334 iRhythm shares were issued at closing. globenewswire.com
- 3iRhythm supplied $10.0 million of working capital to VitalConnect between signing and closing. sec.gov
- 4The company expects enhanced revenue growth starting in 2027. sec.gov
- 5iRhythm reaffirmed its target of a 15% adjusted EBITDA margin for 2027. investing.com
- 6Updated 2026 guidance that includes VitalConnect will be given on November 5 2026. sec.gov
Summary written by AlphAI from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.